Ca(2+) release-activated Ca(2+) channel inhibitors.
Pharm Pat Anal
; 3(2): 171-82, 2014 Mar.
Article
en En
| MEDLINE
| ID: mdl-24588594
ABSTRACT
Ca(2+) release-activated Ca(2+) (CRAC) channels are becoming important targets for therapeutic intervention in several areas of disease, including immunology, allergy and cancer. In parallel to the progression towards reliable methods for measuring CRAC currents and their inhibition, patents have been generated by several companies. In this Patent Review, an analysis of the patents in the CRAC channel inhibition filed is presented. A discussion of the biological methods used in the patents is included. The general interest in this area is growing fast with almost 80% of the patents issued after 2010.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Patentes como Asunto
/
Bloqueadores de los Canales de Calcio
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Pharm Pat Anal
Año:
2014
Tipo del documento:
Article
País de afiliación:
Italia